Focused radiation for locally advanced pancreatic cancer after chemotherapy
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a precise type of radiation therapy guided by MRI for people with locally advanced pancreatic cancer. It aims to treat the tumor while protecting nearby healthy tissue, potentially improving outcomes after chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced pancreatic cancer (adenocarcinoma or adenosquamous carcinoma) that hasn't spread.
- You've had at least 4 months of chemotherapy and completed at least 8 cycles of FOLFIRINOX or 12 doses of gemcitabine/nab-paclitaxel.
- Your cancer has not grown or spread during or after chemotherapy.
- You are 18 or older and able to care for yourself (ECOG performance status 0 or 1).
- Your blood counts and liver function are within acceptable ranges.
- You have not had radiation to the abdomen before, and you are not planning or have not had surgery for pancreatic cancer.
- You are willing to use birth control if applicable and can have an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a way to give radiation therapy for pancreatic cancer using MRI scans to guide the treatment. It aims to make the radiation more precise and possibly more effective, and you will receive chemotherapy first, followed by radiation.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial combines focused radiation with a chemotherapy drug combo to help shrink or control locally advanced pancreatic cancer. If it works, this treatment might make the tumor smaller and improve quality of life.
This trial tests a new treatment called DaRT, which places tiny radioactive devices directly into your pancreatic tumor. It is for people with locally advanced pancreatic cancer that has not spread, after they have already had standard chemotherapy.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.